Menu
Search
|

Menu

Close
X

Second Sight Medical Products Inc EYES.OQ (NASDAQ Stock Exchange Capital Market)

1.76 USD
+0.03 (+1.73%)
As of Jun 22
chart
Previous Close 1.73
Open 1.73
Volume 85,433
3m Avg Volume 65,880
Today’s High 1.77
Today’s Low 1.68
52 Week High 2.58
52 Week Low 0.90
Shares Outstanding (mil) 56.79
Market Capitalization (mil) 65.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
8
FY16
4
FY15
9
EPS (USD)
FY18
-0.165
FY17
-0.533
FY16
-0.859
FY15
-0.562
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
12.71
5.71
Price to Book (MRQ)
vs sector
3.47
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
0.00
16.46
LT Debt to Equity (MRQ)
vs sector
0.00
12.19
Return on Investment (TTM)
vs sector
-141.82
14.38
Return on Equity (TTM)
vs sector
-141.82
16.08

EXECUTIVE LEADERSHIP

Gregg Williams
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Jonathan McGuire
President, Chief Executive Officer, Director, Since 2015
Salary: $394,000.00
Bonus: $86,680.00
John Blake
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Frank Vandeputte
Vice President, General Manager, Since 2017
Salary: --
Bonus: --
Edward Randolph
Vice President - Manufacturing, Since 2007
Salary: $237,084.00
Bonus: $29,280.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

12744 San Fernando Rd Bldg 3
SYLMAR   CA   91342-3853

Phone: +1818.8335000

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

SPONSORED STORIES